uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
October 24 2023 - 7:05AM
uniQure Announces Major Presence at the European Society of
Gene and Cell Therapy (ESGCT) Annual Meeting
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that 12 data presentations, including two
oral presentations, will be delivered at the European Society of
Gene and Cell Therapy (ESGCT) Annual Meeting being held October
24-27 in Brussels, Belgium.
“Our multiple presentations at ESGCT demonstrate
uniQure’s continued leadership in advancing important research
within the field of gene therapy, as well as highlight our
industry-leading expertise in AAV gene therapy manufacturing,”
stated Richard Porter, Ph.D., Chief Business and Scientific Officer
at uniQure. “We look forward to sharing these presentations that
feature our technology and platform experience across numerous
programs.”
Specific details on uniQure’s presentations
taking place at ESGCT include:
- Invited Talk
Title: Update on U.S. Phase I/II Clinical Trial of AMT-130
Gene Therapy for the Treatment of Huntington’s
DiseasePresenter: Richard Porter, Chief Business
and Scientific Officer, uniQureSession Title and
Location: CNS & sensory diseases II, Session 10a, Shed
2ADate and Time: Friday, October 27, 8:30 a.m.
GMT+2
- Title: Gene
therapy for C9ORF72-ALS reduces RNA toxicity and ameliorates
behavioral phenotype in ALS mouse modelPresenter:
Vanessa Zancanella, Sr. Scientist Global Research,
uniQureSession Title and Location: CNS &
sensory diseases I, Session 2c, Maison de la PosteDate and
Time: Tuesday, October 24, 17:00 – 19:00 GMT+2
- Title: Pivotal
safety studies for AMT-260, a novel AAV9-dual microRNA-based vector
targeting GRIK2 for the treatment of temporal lobe epilepsy (Poster
#433)Presenter: Nick Pearson, Sr. Director
Toxicology & Translational Safety, Non-Clinical,
uniQure Poster Session Date and Time:
Wednesday, October 25, 17:00 – 18:15, Thursday, October 26, 20:30 –
21:30 GMT+2
- Title: Production
of low cross-packaging AAV capsid libraries in insect cells (Poster
#166)Presenter: Bas Bosma, Scientific Leader,
Technology Innovation, uniQurePoster Session Date and
Time: Wednesday, October 25, 18:15 – 19:30, Thursday
October 26, 19:30 – 20:30 GMT+2
- Title: Multiplexed
comparison of rationally-designed AAV CNS capsids in vivo (Poster
#181)Presenter: Elena Pimentel, Scientist,
Technology Innovation, uniQurePoster Session Date and
Time: Wednesday, October 25, 17:00 – 18:15, Thursday,
October 26, 20:30 – 21:30 GMT+2
- Title: Silence and
replace as potential treatment for Alzheimer Disease: in concert
lowering toxic APOE and augmenting protective APOE (Poster
#049)Presenter: Amila Zuko, Scientist, Global
Research, uniQurePoster Session Date and Time:
Wednesday, October 25, 17:00 – 18:15, Thursday, October 26, 20:30 –
21:30 GMT+2
- Title: Gene
therapy for synucleinopathies: Combining vectorized antibody and
miRNA-mediated lowering strategies (Poster
#430)Presenter: Kim Wolzak, Jr. Scientist, Global
Research, uniQurePoster Session Date and Time:
Wednesday, October 25, 18:15-19:30, Thursday, October 26,
19:30-20:30 GMT+2
- Title:
Alpha-synuclein lowering and rescue of motor phenotype by
miRNA-based AAV gene therapy in an in vivo Parkinson’s disease rat
model (Poster #420)Presenter: Rhodé van Westen
Erbrink, Scientist, Global Research, uniQurePoster Session
Date and Time: Wednesday, October 25, 18:15-19:30,
Thursday, October 26, 19:30-20:30 GMT+2
- Title: How
uniQure’s modular platform approach drives continuous innovation in
AAV gene therapy development and manufacturing (Poster
#329)Presenter: Erich Ehlert, Director – Process
Development – Chemistry, Manufacturing and Controls,
uniQurePoster Session Date and Time: Wednesday,
October 25, 17:00-18:15, Thursday, October 26, 20:30-21:30
GMT+2
- Title:
Accelerating process development by establishing drug substance
development platform (Poster #191)Presenter:
Giorgio Rainone, Bioprocess Technologist, Drug Substance
Development, uniQurePoster Session Date and Time:
Wednesday, October 25, 17:00-18:15, Thursday, October 26,
20:30-21:30 GMT+2
- Title:
High-throughput process development in rAAV drug substance
manufacturing (Poster #308)Presenter: Yang Jiang,
Associate Director, Drug Substance Development,
uniQurePoster Session Date and Time: Wednesday,
October 25, 18:15-19:30, Thursday, October 26, 19:30-20:30
GMT+2
- Title: Platform
development for AAV manufacturing with the Baculovirus Expression
Vector System (BEVS) (Poster #193)Presenter:
Zandra Félix Garza, Project Manager- BPU – Cells, Seeds and
Research Supply, uniQurePoster Session Date and
Time: Wednesday, October 25, 17:00-18:15, Thursday,
October 26, 20:30-21:30 GMT+2
About uniQure
uniQure’s mission is to reimagine the future of
medicine by delivering innovative cures that transform lives. The
recent approvals of our gene therapy for hemophilia B – an historic
achievement based on more than a decade of research and clinical
development – represent a major milestone in the field of genomic
medicine and ushers in a new treatment approach for patients living
with hemophilia. We are now leveraging our modular and validated
technology and manufacturing platform to advance a pipeline of
proprietary gene therapies for the treatment of patients with
Huntington's disease, refractory mesial temporal lobe epilepsy,
amyotrophic lateral sclerosis (ALS), Fabry disease, and other
severe diseases. www.uniQure.com
uniQure Contacts:
FOR
INVESTORS:Chiara RussoDirect:
617-306-9137Mobile: 617-306-9137c.russo@uniQure.com |
FOR MEDIA:Tom MaloneDirect:
339-970-7558Mobile:339-223-8541 t.malone@uniQure.com |
Uniqure Nv (LSE:0EE0)
Historical Stock Chart
From Jul 2024 to Aug 2024
Uniqure Nv (LSE:0EE0)
Historical Stock Chart
From Aug 2023 to Aug 2024